Cancer cells reprogram metabolism to fuel their growth and survival.

Our focus is anabolic one-carbon (1C) metabolism used by many tumors to drive rapid biomass accumulation. Through selective aberrant expression or genetic mutations, cancer cells activate this pathway to form aggressive tumors. The therapeutic promise of disrupting these 1C pathways is validated by decades of use of approved anti-metabolite therapies targeting related pathways – albeit in non-specific ways and for a limited duration.

Today, aided by an explosion of metabolomics and genomics research, our founding scientists have pinpointed 1C metabolic drivers in cancer, uncovering multiple novel targets for intervention. By selectively inhibiting these targets, we are creating safer and more effective therapies for patients.